Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

BioFocus. (2/11/13). "Press Release: Peter Rehse Joins BioFocus as Senior Director, Structural Biology".

Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
Organisations Organisation BioFocus (divsion of Galapagos)
  Group Galapagos (Group)
  Organisation 2 Shanghai Medicilon Inc.
  Group Medicilon (Group)
Products Product structural biology
  Product 2 fragment-based drug discovery services
Persons Person Rehse, Peter (Galapagos 201302– Senior Director Structural Biology at BioFocus before Shanghai Medicilion + RIKEN)
  Person 2 Hilyard, Kate (Galapagos 201111 VP Biological Sciences at BioFocus)
     


BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK. His responsibilities will include managing the structural biology and fragment-based screening groups within the Biological Sciences division.

Peter joins BioFocus from the Chinese CRO Shanghai Medicilon Inc., where, as Vice President, he was responsible for the strategic business and scientific development of the structural biology and structure-based drug design unit. Prior to this Peter worked at RIKEN Harima Institute, in Japan and has held several academic positions in Japan and Canada. Peter studied for his PhD under the supervision of Professor Tom Blundell at the University of London and undertook post-doctoral research at the Max-Planck Institute.

"With Peter's international credibility we will be able to strengthen and grow our structural biology and fragment screening operation," commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus. "This hire reflects our ongoing commitment to accelerate our client's discovery programs through investing in the right people".


About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capabilities in neurodegenerative diseases, inflammatory diseases and rare and neglected diseases. BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and pre-clinical candidates. The company employs over 150 exceptionally qualified and industry experienced scientists at its research centers in the UK and the Netherlands. Since its foundation in 1997, BioFocus has produced high quality data for its clients, assured by ISO9001 qualification, validated by regular independent inspection of all BioFocus research centers.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top